Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Chugai Pharmaceutical Co. Ltd. ADR is a depositary receipt representing common stock of Chugai Pharmaceutical Co., Ltd., which is listed over the counter in the United States. The underlying issuer is a Japan-based pharmaceutical company that conducts research, development, manufacturing, sales, importation, and exportation of medicines in Japan and international markets. Its portfolio includes oncology and specialty treatments such as Alecensa, Avastin, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, Tecentriq, Actemra, CellCept, Enspryng, Evrysdi, Hemlibra, Mircera, PiaSky, Tamiflu, and Vabysmo. Founded in 1925 and headquartered in Chuo, Japan, the company was formerly known as Chugai Shinyaku Shokai and adopted its current name in 1943. Chugai Pharmaceutical operates as a subsidiary of Roche Holding AG.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CHGC.Y
|
$19.90
|
-8.1% Downside
|
Fair
|
Not available
|
Not available
|
Great
|
0.0%
|
October 27, 2026
|
23.5x
|
5.5x
|
8.3x
|
70.508 B
|
62.347 B
|
0.0%
|
38.9%
|
16.3
|
94.9%
|
85.0%
|
